GLSI (Greenwich LifeSciences, Inc) חוב לטווח קצר להון

Greenwich LifeSciences (GLSI) maintains a high reputation among physicians and investors due to the development of a vaccine against tumor recurrence. This price chart captures the 0.00 indicator. The company is actively developing the GP2 drug, aiming to provide patients with effective protection. Supply stability during trials is guaranteed by the use of advanced cooling systems for the transport of biomaterials.

This ratio determines the dependence of Greenwich LifeSciences (GLSI) on obligations maturing within one year relative to its equity. Analyzing the proportion of short-term debt to equity allows for the identification of critical debt load peaks through comparison with historical data. The metric's dynamics are shaped by the balance between current borrowings and the volume of shareholder equity. For a micro-cap with a single oncology asset and insider dominance, this indicator highlights liquidity risks in capital management.